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S U M M A R Y
Objectives: A high level of HMGB1 (high-mobility group box 1) – a late onset inﬂammatory mediator – is
a marker of lethal sepsis in several infectious diseases. The level of HMGB1 in the plasma of Burkholderia
pseudomallei-infected patients was investigated together with the severity of the disease. The
neutralization of HMGB1 to improve survival was also tested in a mouse model.
Methods: HMGB1 levels in the plasma of 77 septic patients, 40 with B. pseudomallei infection and 37 with
other bacterial infections, were determined by ELISA. Neutralizing antibody against puriﬁed
recombinant HMGB1 was prepared in rabbits (rab-a-HMGB1) and its potential as an adjunct therapy
was evaluated in B. pseudomallei-infected Balb/c mice treated with suboptimal doses of ceftazidime.
Results: The plasma from B. pseudomallei-infected patients showed signiﬁcantly higher HMGB1 levels
than the plasma from other septic patients (median 11.1 ng/ml vs. 7.1 ng/ml). The HMGB1 level was
signiﬁcantly higher in patients with melioidosis who died than in those who survived (median 14.8 ng/
ml vs. 9.2 ng/ml). Moreover, the HMGB1 level was signiﬁcantly correlated with the clinical severity score
(SOFA score). In the mouse study, although the rab-a-HMGB1 by itself could not improve the survival
outcome of B. pseudomallei-infected mice, it could nevertheless enhance the effectiveness of suboptimal
doses of ceftazidime in the treatment of these animals.
Conclusion: The level of HMGB1 in septic melioidosis patients can be used as a marker of late severe
sepsis. Neutralizing antibody to HMGB1 may be used as an adjunct therapy to improve the outcome of
melioidosis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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HMGB1 (high-mobility group box 1), also known as high-
mobility group protein 1 (HMG-1), is a 30-kD non-histone nuclear
protein functioning as a transcriptional regulator essentially for
cellular physiology.1,2 Under certain pathological insults, such as
inﬂammation or necrotic cell death, HMGB1 transmigrates from
the nucleus to the outside of cells, where it functions as a potent
proinﬂammatory mediator by interacting with toll-like receptors* Corresponding author. Tel.: +66 43 363808; fax: +66 43 348385.
E-mail addresses: sura_wng@kku.ac.th, surawng@gmail.com
(S. Wongratanacheewin).
http://dx.doi.org/10.1016/j.ijid.2014.07.025
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).TLR-2, -4, or the receptor for advanced glycation end-products
(RAGE) presenting on other cells.2,3 In the scenario of sepsis in
humans, HMGB1, as well as many other pro- and anti-inﬂamma-
tory cytokines, is released into the circulation and participates in
the pathogenesis, but with kinetics distinctly different from the
others. The kinetics of HMGB1 release during sepsis is relatively
slow and thus it is classiﬁed as a late onset mediator of sepsis. The
few sepsis mediators known so far grouped into this classiﬁcation
include HMGB1, macrophage migration inhibitory factor (MIF),
and complement factor 5a (C5a).4,5 A feature of late onset
mediators in releasing kinetics makes HMGB1 a promising factor
to be targeted as an adjunctive therapy in the treatment of
sepsis.6,7 In animal sepsis models using cecal ligation and punctureciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Types of specimens and bacterial identiﬁcation in all patients
Bacteria identiﬁed n (%) Specimens (n)
Burkholderia pseudomallei 40 (51.9%) Blood (28), blood + sputum (3),
sputum (7), pus (1), pleural ﬂuid (1)
Klebsiella pneumoniae 11 (14.3%) Sputum (8), blood (3)
Escherichia coli 10 (13.0%) Blood (8), sputum (2)
Pseudomonas aeruginosa 4 (5.2%) Sputum (1), blood (1), pus +
sputum (1), urine (1)
Acinetobacter spp 3 (3.9%) Blood (2), sputum (1)
Enterococcus 3 (3.9%) Sputum (2), pus (1)
Beta-hemolytic streptococci 2 (2.6%) Blood (2)
Staphylococcus aureus 2 (2.6%) Blood (2)
Salmonella spp 1 (1.3%) Blood (1)
Streptococcus pneumoniae 1 (1.3%) Sputum (1)
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bodies has been shown to increase animal survival rates.8,9
In northeastern Thailand, one of the most common etiologic
organisms for community-acquired septicemia is Burkholderia
pseudomallei, a Gram-negative bacterium that naturally inhabits
soil.10 Although infection by this organism can manifest in various
clinical forms, the most serious one, which is not uncommon, is the
septicemic form. The mortality rate of patients with the septicemic
form of B. pseudomallei infection, or so-called septicemic melioi-
dosis, has been shown to be as high as 40%, despite the use of
appropriate antibacterial agents.11 It has been shown previously
that many pro- and anti-inﬂammatory cytokines, such as
interleukin (IL)-6, IL-10, etc. play a role in the pathological
processes of septicemic melioidosis, as well as having a predictive
value with regard to the clinical outcome.12,13
In order to determine whether or not there is a relationship
between HMGB1 and septicemic melioidosis, we performed a
prospective observational study on patients in the early stages of
clinical sepsis who were likely to have B. pseudomallei infection as
the etiology. These patients were hospitalized in two provincial
general hospitals (300 beds) in northeastern Thailand. As a
relationship between HMGB1 and survival was conﬁrmed in these
patients, it was hypothesized that neutralization of serum HMGB1
might have a value in treating septicemic melioidosis. Therefore an
experimental mouse model was employed to determine whether
the neutralization of HMGB1 with polyclonal antibodies alone or
when used in conjunction with suboptimal doses of ceftazidime
could improve survival in cases of infection.
2. Materials and methods
2.1. Patients
Adult patients with community-acquired sepsis likely to have
an etiology of B. pseudomallei, who were newly admitted to the
hospitals of Nong Khai and Mahasarakham during 2008–2010,
were included in this study. These two hospitals are located in the
upper region of northeastern Thailand, an area with a high
prevalence of human melioidosis.14
Clinical sepsis was deﬁned as the appearance of systemic
inﬂammatory response syndrome (SIRS) with a report of at least
one positive culture from a body ﬂuid specimen.15 SIRS was
conﬁrmed in the presence of two or more of the following: a body
temperature >38 8C or <36 8C, a heart rate >90 beats per min, a
respiratory rate >20 breaths per min or the necessity for
respiratory assistance, and a white blood cell count >12  109
cells/l or the presence of >10% band form neutrophils. Since it had
been reported in a previous local survey that B. pseudomallei
infection accounted for approximately 5–10% of community-
acquired sepsis, only those cases with a clinical appearance highly
suggestive of melioidosis were enrolled. Patients with a high
probability of melioidosis included those with a history of
environmental exposure, rapid clinical progression, the presence
of diabetes, or otherwise a clinical manifestation that was not
indicative of other certain organisms. Despite this selection
process, when the culture results were reported, approximately
half of the enrolled patients were not infected with B. pseudomallei;
their plasma samples were studied for HMGB1 and they were
placed in a non-B. pseudomallei sepsis group. Patients who were
culture-negative or had a known history of being immunocom-
promised (e.g. HIV or cancer chemotherapy), were excluded from
the study. The types of positive specimen, bacteria isolated, and the
percentage of each infection are shown in Table 1.
Soon after enrollment and with signed informed consent,
venous blood was collected in ethylenediaminetetraacetic acid
(EDTA) and the plasma was then separated and stored at 80 8Cuntil the HMGB1 measurement was performed. The clinical
severity at the time of blood sample collection was assessed with
the SOFA score (Sequential Organ Failure Assessment).16 The study
protocol was approved by the ethics committees of the Ministry of
Public Health (Ref. 103/2551) and Khon Kaen University (Ref.
HE510905).
2.2. Rabbit anti-mouse HMGB1 polyclonal antibodies
A commercially available mouse HMGB1 expression vector
(pReceiver-B11x; Capital Bioscience, Rockville, MD, USA) was
transfected into Escherichia coli DH5-a. Recombinant protein was
then expressed and puriﬁed using Ni-Sepharose (HisTrap FF; GE
Healthcare, Pittsburg, PA, USA). Polyclonal antibodies were
produced in a female New Zealand rabbit immunized four times
(days 0, 14, 28, and 42) with subcutaneous injections of 0.5 mg
recombinant protein along with complete Freund’s adjuvant (CFA)
for the ﬁrst injection and incomplete Freund’s adjuvant (IFA) for
the others, according to the protocol described by Lin et al.17 The
antibodies were then obtained by puriﬁcation using ammonium
sulfate precipitation, followed by Hi-Trap Protein G Afﬁnity
column and Hi-Trap Desalting columns (GE Healthcare Pittsburg,
PA, USA), as per the manufacturer’s instructions. The reactivity of
the antibodies produced against mouse HMGB1 was conﬁrmed by
probing with the recombinant protein in a Western blot and
comparison with other commercially available rabbit polyclonal
antibodies against HMGB1 (Abcam, Cambridge, MA, USA). The
latter conﬁrmed the sequence homology of the constructed
recombinant protein (Figure 1).
2.3. Mouse model of B. pseudomallei infection
Six- to eight-week-old BALB/c mice were obtained from the
National Laboratory Animal Center, Mahidol University. Experi-
ments were done with the ethical approval of the Animal Ethics
Committee of the Faculty of Medicine, Khon Kaen University (Ref.
AE04/53). At the time-point 2 h, mice were treated with either
polyclonal anti-mouse HMGB1 (rab-a-HMGB1) or isotype control
antibodies at 2 mg/mouse via an intraperitoneal injection. At time-
point 0 h, mice were then challenged intraperitoneally with a
highly virulent B. pseudomallei strain A2 at inoculum sizes of 3–10
LD50 (median lethal dose). At indicated time-points, aliquots of
mouse blood were taken from the periorbital plexus.
2.4. Protocol for adjunct treatments
Animals were infected intraperitoneally with a 5-LD50 log phase
culture of B. pseudomallei in a volume of 100 ml (day 0). They were
then divided randomly into three groups (four per group). The
animals received either phosphate buffered saline (PBS) (control),
2 mg of rab-a-HMGB1 plus ceftazidime (1/4 of the optimal dose for
Figure 1. Western blot analysis of rabbit polyclonal antibodies against HMGB1: the
recombinant mouse HMGB1 (1 mg) as separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose
membrane by Western blot. Reactivity of produced antibodies against mouse
HMGB1 was probed with goat anti-rabbit horseradish peroxidase (HRP)
(Invitrogen, Camarillo, CA, USA); chemiluminescent HRP substrate (Thermo
Scientiﬁc, Rockford, IL, USA) was then added. Commercially available rabbit
polyclonal antibodies against HMGB1 (Abcam, Cambridge, MA, USA) and pre-
immune rabbit IgG were used as negative controls.
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(normal rabbit IgG) plus ceftazidime (300 mg/kg) (isotype/Ctz) 2 h
before being infected. Ceftazidime (300 mg/kg) was administered
intraperitoneally twice daily for 10 days (Table 2). Survival rates of
the mice were observed for 14 days. All studies were done in two
independent experiments.
2.5. Determination of HMGB1
The HMGB1 levels in plasma in both humans and mice were
subsequently measured using commercially available ELISA kits
(IBL International GmbH, Hamburg, Germany).Table 2
Protocol for adjunct treatmentsa
Group No. No. of
mice
Adjunct treatment
with:b
Antibiotic treatment
with:c
I: Control 4 PBS None
II: a-HMGB1/Ctz 4 Rabbit IgG anti-HMGB1 Ceftazidime
III: Isotype/Ctz 4 Normal rabbit IgG Ceftazidime
PBS, phosphate buffered saline.
a All mice were infected intraperitoneally with 5 LD50 of Burkholderia
pseudomallei on day 0.
b 2 mg/mouse of antibodies or IgG was given intraperitoneally 2 h before
infection.
c 300 mg/kg of ceftazidime was given on day 1 and twice daily for 10 days.2.6. Statistical analysis
The statistical signiﬁcance of differences was evaluated using
the Student’s t-test, Pearson Chi-square test, or Mann–Whitney U-
test. Statistical signiﬁcance was deﬁned as p < 0.05.
3. Results
Seventy-seven adult patients with clinically documented sepsis
(SIRS), plus a retrospective positive culture from any body ﬂuid
specimen, were enrolled into the study; 40 had B. pseudomallei
sepsis (B. pseudomallei sepsis group) and the other 37 had other
bacterial sepsis (non-B. pseudomallei sepsis group). Clinical
parameters in the two groups are shown in Table 3.
Patients in the B. pseudomallei sepsis group were found to be
signiﬁcantly younger than those in the non-B. pseudomallei sepsis
group (mean 49.8 years vs. 60.3 years; p < 0.001); this ﬁnding is in
accordance with previous reports,19 supporting that the acquisi-
tion of B. pseudomallei requires environmental exposure, which is
usually more frequent in persons of actively working age. Severity
parameters, in terms of 1-month death rates and SOFA scores, were
not different between the two groups. B. pseudomallei sepsis
patients had a higher number of reports showing a positive blood
culture. Among those with non-B. pseudomallei sepsis, the
causative organisms and their frequencies are shown in Table 1.
For the determination of HMGB1 levels, patient venous blood
samples were collected as soon as possible once clinical sepsis was
conﬁrmed, regardless of culture results at the time, with a mean 
standard deviation (SD) interval after clinical onset of 2.8  1.8 days
for the B. pseudomallei sepsis group and 1.5  0.9 days for the non-B.
pseudomallei sepsis group. HMGB1 measurements showed that
patients with B. pseudomallei sepsis had median plasma HMGB1
levels signiﬁcantly higher than non-B. pseudomallei sepsis patients
(11.1 ng/ml vs. 7.1 ng/ml, p = 0.001, Mann–Whitney U-test;
Figure 2A). Among those with B. pseudomallei sepsis, plasma HMGB1
levels were higher in those with a 1-month outcome of death than in
those who survived (median 14.8 ng/ml vs. 9.2 ng/ml, p = 0.038;
Figure 2B). The relationship between 1-month death outcome and
HMGB1 was also observed when considering the two groups as a
whole (data not shown). A signiﬁcant but weak correlation between
SOFA scores and HMGB1 levels among subjects overall was observed
in this study (Spearman’s rho = 0.236, p = 0.041; Figure 2C).
As a relationship between HMGB1 and survival was conﬁrmed
in these patients, it was hypothesized that neutralization of mouse
HMGB1 may improve survival in the mouse model of septicemic
melioidosis. To test this hypothesis, a batch of rabbit polyclonal
antibodies against mouse HMGB1 was produced. Anti-HMGB1
antibodies or IgG for controls at 2 mg per mouse was injected via
intraperitoneal route 2 h prior to challenge with the highly virulent
B. pseudomallei strain A2, also via the intraperitoneal cavity at anTable 3
Clinical observations (SOFA score) and details of patients included in this study
(N = 77)
Overall Bp sepsis Non-Bp sepsis p-Value
Number of patients 77 40 37
Age, years, mean  SD 49.8  12.8 60.3  12.9 <0.001b
Male, n (%) 31 (77.5%) 28 (75.7%) 0.85c
SOFA score, mean  SD 6.3  4.8 6.0  3.6 0.133b
Deatha, n (%) 16 (40.0%) 12 (32.4%) 0.490c
Blood culture positive, n (%) 32 (80.0%) 19 (51.4%) 0.008c
SOFA, Sequential Organ Failure Assessment; Bp, Burkholderia pseudomallei; SD,
standard deviation.
a Death within 1 month.
b Student’s t-test.
c Pearson Chi-square test.
Figure 2. HMGB1 levels in the Burkholderia pseudomallei group and the other
bacterial infections group. The plasma of patients with melioidosis and patients
with other bacterial infections was collected as soon as possible after sepsis
appeared clinically, regardless of the culture results at the time, and the HMGB1
level was detected by ELISA (A). The levels of HMGB1 were compared between
patients with melioidosis who died and those who survived (B). The correlation
between the SOFA score and the B. pseudomallei and non-B. pseudomallei sepsis
groups is shown (C). Asterisks (*) indicate a signiﬁcant difference (p < 0.05).
Figure 4. Effect of suboptimal antibiotic doses with/without anti-HMGB1 on
survival rates in the treatment of Burkholderia pseudomallei-infected mice. Three
groups of mice (four mice/group; groups I–III) were infected with 5 LD50 of B.
pseudomallei A2 on day 0. The treatments were then performed on groups II and III.
Groups II and III were treated with 300 mg/kg of ceftazidime with 2 mg of rabbit IgG
anti-HMGB1 or 2 mg of normal rabbit IgG 2 h, respectively, before infection.
Ceftazidime was administered intraperitoneally twice daily for 10 days. Group I was
treated with phosphate buffered saline (PBS) as control. Mice were observed daily
and the percentage of surviving mice in all groups plotted against time. Data
represent the results of two independent experiments. The asterisk (*) indicates a
signiﬁcant difference (p < 0.05).
Figure 3. The survival rate and HMGB1 levels in mice with melioidosis. Anti-
HMGB1 antibodies or control IgG at 2 mg per mouse was injected via
intraperitoneal route 2 h prior to challenge with 3 LD50 of Burkholderia
pseudomallei strain A2 via intraperitoneal route. The plasma HMGB1 levels in
both groups were detected at 52 h post infection by ELISA (A). The survival patterns
of the two treatment arms are shown (B). The asterisk (*) indicates a signiﬁcant
difference (p < 0.05).
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neutralized, as shown by the plasma HMGB1 levels, which were
signiﬁcantly decreased at 52 h post infection in the anti-HGMB1
treatment group (Figure 3A, p = 0.035), the survival patterns of the
two treatment groups were not different (Figure 3B, p = 0.942). In
both treatment arms, B. pseudomallei killed mice as early as 48 h,
and all mice died within 6 days. Similar survival rates were
observed in two other experiments, one using an inoculum size of
10 LD50 and the other using a different time schedule for anti-
HMGB1 injection (two injections of 0.5 mg/mouse, at post
infection times of 20 h and 39 h; data not shown). Therefore, it
can be summarized that neutralization of HMGB1 failed to improve
survival in a severe sepsis model of B. pseudomallei infection.
When anti-HMGB1 was used as an adjuvant therapy, the a-
HMGB1/Ctz group had a 30% survival rate, whereas all mice in the
untreated control group and in the isotype/Ctz group were dead
within 11 days (Figure 4). These results indicate that the anti-
HMGB1 had the capability of improving the outcome of the B.
pseudomallei-infected mice receiving antibiotic therapy.
4. Discussion
There is growing evidence that late onset inﬂammatory
mediators may play an important role in the pathological process
of sepsis. One of the most common manifestations of B.
pseudomallei infection is highly fatal clinical sepsis. It was therefore
hypothesized that HMGB1, which is a late onset inﬂammatory
mediator, might have a role in septicemic melioidosis. Recently,
MIF, another late onset mediator of sepsis, was shown to
participate in the pathogenesis of human melioidosis as its
expression levels correlated with the clinical outcome.20In the current study, it was demonstrated that, in a similar
pattern to that shown elsewhere, plasma HMGB1 was increased in
sepsis in both B. pseudomallei infection and in other non-speciﬁc
bacterial infections. A remarkable distinction between these
different etiologies, however, was the higher levels of HMGB1 in
B. pseudomallei infections. If one classiﬁes sepsis of organisms other
J. Charoensup et al. / International Journal of Infectious Diseases 28 (2014) 111–116 115than B. pseudomallei as a common pool of pathological etiology, it is
possible that the higher HGMB1 levels in B. pseudomallei sepsis
contributed to some degree to the pathological differences. One
possible pathological difference is the difference in kinetics of
bacterial multiplication, together with differences in kinetics of
host responses opposing the bacterial multiplication and the tissue
destruction. Differences in the percentage of subjects with positive
blood cultures (Table 1), or in other words differences in the
numbers of organisms making up the bacteremia in an equal blood
volume between the B. pseudomallei sepsis and the non-B.
pseudomallei sepsis groups, is another line of evidence supporting
the role of host–pathogen interaction kinetics mentioned above. It
has also been shown previously, in a similar scenario of clinical
sepsis, that the number of bacteria per milliliter blood volume in B.
pseudomallei infection differs from the number of other bacteria.21
With regard to HMGB1 levels and their clinical associations,
HMGB1 levels in B. pseudomallei sepsis were found to be associated
with 1-month mortality outcomes. This ﬁnding is in accordance
with those of previous reports describing other organisms in
sepsis,2 as well as in the non-B. pseudomallei group in the present
study. Thus, it can be proposed that HMGB1 is another mediator
that has an association with clinical outcomes, particularly in
mortality outcomes. Nevertheless, the association with clinical
severity in terms of the correlation of SOFA scores and HMGB1
levels was found to be less prominent when compared with the
association of HMGB1 with the mortality outcome.
With the ﬁndings in humans as demonstrated, it could be
hypothesized that targeting HMGB1 in an animal model of
septicemic melioidosis would improve animal survival. In this
respect, a mouse model of acute sepsis with B. pseudomallei was
used in which BABL/c mice were infected via an intraperitoneal
injection of a highly virulent B. pseudomallei strain. Under these
infection conditions with this bacterial strain, wherein the LD50
within 1 month was only at 20 CFU,22 the mouse would develop
lethality within 3 days when the inoculum sizes were of 10  to
20  LD50, and thus this infection scenario would represent acute
sepsis rather than chronic infection. In order to prevent rapid
stimulation of HMGB1 after infection, the anti-HMGB1 was
injected 2 h before bacteria were given. This design is similar to
that used in a previous study using anti-MIF in the treatment of the
mouse with melioidosis.19 Nevertheless, when this model was
applied, HMGB1 neutralization with rabbit polyclonal antibodies
failed to demonstrate protective effects of the treatment, although
such antibodies could signiﬁcantly reduce HMGB1 levels
(Figure 3A). The failure of protection might be due to the
overwhelming bacteremia in treated animals (data not shown).
Therefore the use of ceftazidime, one of the drugs of choice for
melioidosis, together with anti-HMGB1 as an adjunct therapy was
tested. The limited results demonstrated that the use of rab-a-
HMGB1 as an adjunct therapy led to a 30% survival rate, whereas all
mice in the control and untreated groups were dead within
11 days. This anti-HMGB1 might lower the excessive and
unregulated levels of proinﬂammatory cytokines while ceftazi-
dime controls the bacteremia that leads to death. It is possible that
with higher doses and/or higher neutralizing capacity of antibody,
or more optimal administration procedures, a higher rate of
success would be achieved. Ongoing experiments along these lines
are being planned.
Before using the antibody to neutralize HMGB1, the protocol
also employed a range of ethyl pyruvate treatments as a
preliminary method for HMGB1 neutralization in the same animal
model, but did not see any protective effects (data not shown).
Ethyl pyruvate is a small organic molecule of metabolic
intermediates shown previously in other models to have the
ability to reduce HMGB1 release upon stimulation.23,24 Treatment
with ethyl pyruvate was also shown to improve survival in a sepsismodel using CLP.23,25 The reason for the discrepancy in the
protective effect of HMGB1 neutralization between the present
animal model of acute lethal B. pseudomallei infection and other
models of sepsis, in a majority the CLP models, is currently
unknown. Since the insulting organisms of CLP, which are likely to
be commensal organisms, are clearly different from highly
pathogenic organisms such as B. pseudomallei, particularly with
respect to host immunity, one might speculate that the differences
in host–pathogen interaction at the cellular level, especially in
bacterial growth kinetics, is a possible reason for the discrepancy.
Differences in bacterial growth kinetics in interactions with the
host have been exempliﬁed in an in vitro assay that showed that
the virulent B. pseudomallei can continue to grow inside
phagocytes, even at a relatively low multiplication of infection
(MOI), i.e. at MOI of 1.26 In contrast, in another similar assay
system, this type of growth kinetics was found to be uncommon for
E. coli, a representative of the commensal bacteria.27 Differences at
the cellular level of the host–pathogen interaction then lead to
diversiﬁcation of subsequent immunology and pathology, and thus
may result in the discrepancy in the protective effect of HMGB1
neutralization.
In conclusion, the level of HMGB1 in septic melioidosis patients
could be used as a marker of late severe sepsis. Although
neutralizing antibody to HMGB1 itself could not protect mice
from infection, it might be used as an adjunct therapy to improve
the outcome of melioidosis.
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